Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients

Hemodialysis International

Volumn 13, Issue 3, 2009, Pages 271-277

  Peres, Aline T ^a   Dalboni, Maria A ^a   Canziani, Maria E ^a   Manfredi, Silvia R ^a   Carvalho, Jose Tarcisio G ^a   Batista, Marcelo C ^a   Cuppari, Lilian ^a   Carvalho, Aluisio B ^a   Moyses, Rosa M A ^b   Guimarães, Nadia ^a   Jorgetti, Vanda ^b   Andreoli, Maria C ^a   Draibe, Sergio A ^a   Cendoroglo, Miguel ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hemodialysis; Inflammation; Phosphate binders; Reactive oxygen species

Indexed keywords

C REACTIVE PROTEIN; CALCIUM ACETATE; REACTIVE OXYGEN METABOLITE; SEVELAMER;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; INFLAMMATION; LONG TERM CARE; MALE; OXIDATIVE STRESS; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; SMOKING;

ACETATES; ADULT; BIOLOGICAL MARKERS; CALCIUM COMPOUNDS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHATE-BINDING PROTEINS; POLYAMINES; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 69249196045     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00369.x     Document Type: Article

References (24)

1. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellstrom B. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol. 2005; 18:721-726.
2. Diepeveen SH, Verhoeven GH, van der Palen J, et al. The effect of the initiation of renal replacement therapy on lipid profile and oxidative stress during the first 6 months of treatment. Clin Chim Acta. 2005; 361:112-118.
3. Karamouzis I, Sarafidis PA, Karamouzis M, et al. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol. 2007; 28:397-404.
4. Massy ZA, Mazière S, Kamel M, et al. Impact of inflammation and stress oxidative on vascular calcifications in chronic kidney disease. Pediatr Nephrol. 2005; 20:380-382.
5. Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins? Kidney Int. 2003; 84(Suppl):S11-S14.
6. Horl WH. Hemodialysis membranes: Interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol. 2002;(Suppl 1):S62-S71.
7. Ringoir S, Vanholder R. Phagocytic function in the uremic patient. Contrib Nephrol. 1992; 100:15-24.
8. Shimoishi K, Anraku M, Kitamura K, et al. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxil sulfate in the systemic circulation in renal failure. Pharm Res. 2007; 24:1283-1289.
9. Cendoroglo M, Jaber BL, Balakrishnan VS, Perianayagam M, King AJ, Pereira BJ. Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol. 1999; 10:93-100.
10. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2005; 58:1758-1764.
11. Cozzolino M, Dusso AS, Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol. 2001; 12:2511-2516.
12. Iwasaki Y, Yamato H, Nii-Kono T, et al. Uremic toxin and bone metabolism. J Bone Miner Metab. 2006; 24:172-175.
13. Amin N. The impact of improved phosphorus control: Use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant. 2002; 17:340-345.
14. Yamada K, Fujimoto S, Tokura T, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail. 2005; 27:361-365.
15. De Smet R, Thermote F, Lameire N, Vanholder R. Sevelamer hydrochloride (Renagel ®) adsorbs the uremic compound indoxyl sulfate. J Am Soc Nephrol. 2003; 14:206A.
16. Kamisako T, Ogawa H, Yamamoto K. Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat. J Gastroenterol Hepatol. 2007; 22:1832-1837.
17. Tahara H, Tsujimoto Y, Shoji T, Inaba M, Tabata T, Nishizawa Y. Introduction to sevelamer hydrochloride and its clinical effects. Ther Apher Dial. 2005; 9(Suppl 1):S2-S6.
18. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005; 149:820-825.
19. Nikolov I, Joki N, Drueke T, Massy Z. Beyond phosphate-Role of uraemic toxins in cardiovascular calcification. Nephrol Dial Transplant. 2006; 21:3354-3357.
20. Barreto DV, Barreto F, Carvalho AB, et al. Bone and the relationship with inflammation and coronary calcification-Results of the BRIC study. Nephron Clin Pratc. 2008; 110:c273-c283.
21. Schucker JJ, Ward KE. Hyperphosphatemia and phosphate binders. Am J Health Syst Pharm. 2005; 62:2355-2361.
22. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. 1999; 14:2907-2914.
23. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. Arthritis Rheum. 2005; 52:290-295.
24. DeSmet R, Thermote F, Lameire N, Vanholder R. Sevelamer hydrochloride (Renagel) adsorbs the uremic compounds indoxyl sulfate, indole and p-cresol [Abstract]. J Am Soc Nephrol. 2004; 15:505A.